FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and clearing streamlined pathway for first oral anabolic osteoporosis ...

Significant regulatory advances for lead candidate EB613 streamline Phase 3 clinical development and reduce regulatory hurdles. These 10 stocks could mint the next wave of millionaires › Entera Bio ...

Chief Executive Miranda Toledano said Entera's agreement with the FDA allows Enterea to advance its clinical-development program without having to wait for FDA's qualification of the Study to Advance ...

Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis Provided by GlobeNewswire Jul 28, 2025, 4:30:00 AM ...

--Entera Bio Ltd., a leader in the development of oral peptides and proteins replacement therapies, announced highlights from Dr. Rachel B Wagman’ s oral presentation at the 2025 World Congress ...

Opko Health and Entera Bio have announced a partnership and licence agreement to progress the development of the first oral dual agonist glucagon-like peptide-1 (GLP-1)/glucagon, aiming to provide ...

Entera Bio Ltd. is currently sporting a Zacks Rank of #2 (Buy). Over the past three months, the Zacks Consensus Estimate for ENTX's full-year earnings has moved 8% higher.

Furthermore, the FDA agreed with Entera’s proposed enrollment of post-menopausal women with osteoporosis based on a BMD T-score of ≤-2.5 to -3.0 and no major fracture history.

Real estate technology platform Entera announced Monday that it raised $7.5 million in funding. Entera provides an AI and machine learning-powered real estate investment platform that helps ...

OPKO Health and Entera Bio are partnering to develop a once-daily pill for patients with obesity and other disorders, the companies said on Monday.

Entera, a Real Estate SaaS Platform for Investors, appoints Jeffrey Belanger as CPO, and Alejandro Guerrero as SVP of Growth, to the executive team.